



For Immediate Release

Symic Appoints Carolyn Bertozzi, Ph.D., to Scientific Advisory Board

SAN FRANCISCO, June 28, 2016 – Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Carolyn Bertozzi, Ph.D., has been appointed as a member of the company’s Scientific Advisory Board.

“Dr. Bertozzi is well known for her groundbreaking work in chemical biology, specifically in cell adhesion and cell surface recognition,” said Seema Kantak, Chief Scientific Officer of Symic. “It would be difficult to find a more distinguished researcher to assist in our efforts to develop therapies that are inspired by new understanding of the biology of the extracellular matrix. We are extremely grateful to have Dr. Bertozzi contribute to our efforts.”

“I’m encouraged by the progress that Symic has made in developing therapeutic applications that address areas of biology that have received relatively little attention,” said Dr. Bertozzi. “I look forward to helping realize the many possibilities of new types of therapeutics that influence cellular boundaries and the extracellular matrix.”

Professor of Chemistry and of Radiology and of Chemical and Systems Biology at Stanford University, Dr. Carolyn Bertozzi, Ph.D., is also a member of the National Academy of Sciences, the Institute of Medicine, the German Academy of Sciences - Leopoldina, the American Academy of Arts and Sciences and the National Academy of Inventors. Dr. Bertozzi is the recipient of multiple awards, including the Lemelson-MIT Prize, the Albert Hofmann Medal, and a MacArthur Foundation “Genius” Award and is also a Fellow of the American Association for the Advancement of Science. Dr. Bertozzi received her undergraduate degree from Harvard University, a Ph.D. from the University of California at Berkeley. Dr. Bertozzi has been recognized with honorary doctorate degrees from Brown University, Duke University and the Freie University of Berlin.

About Symic

Symic is a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissue. The ECM plays a critical role in a wide variety of processes involved in acute and chronic indications. Symic’s proprietary compounds function like proteoglycans, which are naturally occurring macromolecules that play important structural and regulatory functions in the ECM. Symic currently has two clinical candidates, one in vascular injury and the other in osteoarthritis. In addition, Symic has several preclinical programs in oncology, fibrosis and CNS disorders.

For additional information please visit the company’s website at <http://www.symic.bio>, LinkedIn page www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.

###

Media Contacts

David Schull or Rich Allan
Russo Partners, LLC
(212) 845-4271
(646) 942-5588
david.schull@russopartnersllc.com
rich.allan@russopartnersllc.com